Charles Duncan
Stock Analyst at Cantor Fitzgerald
(3.49)
# 934
Out of 5,093 analysts
226
Total ratings
46.48%
Success rate
21.03%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $6.30 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $26.76 | +4.63% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $168.94 | -11.21% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $147.56 | +3.69% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $14.63 | -4.31% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $81.12 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $10.54 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $33.00 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $38.92 | +49.02% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $29.41 | +46.21% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $64.13 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.73 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $154.99 | +0.01% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.86 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $19.69 | +77.76% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $6.14 | +111.73% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.91 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.75 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.00 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.45 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $23.16 | +46.80% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $47.40 | +5.49% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $5.71 | -12.43% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.37 | +992.90% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.05 | +280.95% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $44.53 | +30.25% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.59 | +69,082.39% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $5.86 | +1,265.19% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.00 | +200.00% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $4.34 | +153.46% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $7.55 | +58.94% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $6.78 | +2,377.88% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.69 | +643.49% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $30.51 | +555.52% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.58 | +153.16% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $3.20 | +650.00% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $2.09 | +6,789.95% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.27 | +214.96% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $62.88 | -37.98% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $82.98 | -81.92% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.50 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $5.61 | +3,108.56% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.30
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $26.76
Upside: +4.63%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $168.94
Upside: -11.21%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $147.56
Upside: +3.69%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $14.63
Upside: -4.31%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $81.12
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.54
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $33.00
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $38.92
Upside: +49.02%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $29.41
Upside: +46.21%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $64.13
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.73
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $154.99
Upside: +0.01%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.86
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $19.69
Upside: +77.76%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $6.14
Upside: +111.73%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.91
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.75
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.00
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.45
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $23.16
Upside: +46.80%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $47.40
Upside: +5.49%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $5.71
Upside: -12.43%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.37
Upside: +992.90%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.05
Upside: +280.95%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $44.53
Upside: +30.25%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.59
Upside: +69,082.39%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $5.86
Upside: +1,265.19%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.00
Upside: +200.00%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $4.34
Upside: +153.46%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $7.55
Upside: +58.94%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $6.78
Upside: +2,377.88%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.69
Upside: +643.49%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $30.51
Upside: +555.52%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.58
Upside: +153.16%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $3.20
Upside: +650.00%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $2.09
Upside: +6,789.95%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.27
Upside: +214.96%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $62.88
Upside: -37.98%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $82.98
Upside: -81.92%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.50
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $5.61
Upside: +3,108.56%